Machine learning could improve our ability to determine whether a new drug works in the brain, potentially enabling researchers to detect drug effects that would be missed entirely by conventional statistical tests, finds a new UCL study published today in Brain.
“Current statistical models are too simple. They fail to capture complex biological variations across people, discarding them as mere noise. We suspected this could partly explain why so many drug trials work in simple animals but fail in the complex brains of humans. If so, machine learning capable of modelling the human brain in its full complexity may uncover treatment effects that would otherwise be missed,” said the study’s lead author, Dr Parashkev Nachev (UCL Institute of Neurology).
To test the concept, the research team looked at large-scale data from patients with stroke, extracting the complex anatomical pattern of brain damage caused by the stroke in each patient, creating in the process the largest collection of anatomically registered images of stroke ever assembled. As an index of the impact of stroke, they used gaze direction, objectively measured from the eyes as seen on head CT scans upon hospital admission, and from MRI scans typically done 1-3 days later.
They then simulated a large-scale meta-analysis of a set of hypothetical drugs, to see if treatment effects of different magnitudes that would have been missed by conventional statistical analysis could be identified with machine learning. For example, given a drug treatment that shrinks a brain lesion by 70%, they tested for a significant effect using conventional (low-dimensional) statistical tests as well as by using high-dimensional machine learning methods.
The machine learning technique took into account the presence or absence of damage across the entire brain, treating the stroke as a complex “fingerprint”, described by a multitude of variables.
“Stroke trials tend to use relatively few, crude variables, such as the size of the lesion, ignoring whether the lesion is centred on a critical area or at the edge of it. Our algorithm learned the entire pattern of damage across the brain instead, employing thousands of variables at high anatomical resolution. By illuminating the complex relationship between anatomy and clinical outcome, it enabled us to detect therapeutic effects with far greater sensitivity than conventional techniques,” explained the study’s first author, Tianbo Xu (UCL Institute of Neurology).
The advantage of the machine learning approach was particularly strong when looking at interventions that reduce the volume of the lesion itself. With conventional low-dimensional models, the intervention would need to shrink the lesion by 78.4% of its volume for the effect to be detected in a trial more often than not, while the high-dimensional model would more than likely detect an effect when the lesion was shrunk by only 55%.
“Conventional statistical models will miss an effect even if the drug typically reduces the size of the lesion by half, or more, simply because the complexity of the brain’s functional anatomy—when left unaccounted for—introduces so much individual variability in measured clinical outcomes. Yet saving 50% of the affected brain area is meaningful even if it doesn’t have a clear impact on behaviour. There’s no such thing as redundant brain,” said Dr Nachev.
The researchers say their findings demonstrate that machine learning could be invaluable to medical science, especially when the system under study—such as the brain—is highly complex.
“The real value of machine learning lies not so much in automating things we find easy to do naturally, but formalising very complex decisions. Machine learning can combine the intuitive flexibility of a clinician with the formality of the statistics that drive evidence-based medicine. Models that pull together 1000s of variables can still be rigorous and mathematically sound. We can now capture the complex relationship between anatomy and outcome with high precision,” said Dr Nachev.
“We hope that researchers and clinicians begin using our methods the next time they need to run a clinical trial,” said co-author Professor Geraint Rees (Dean, UCL Faculty of Life Sciences).
Learn more: Improving clinical trials with machine learning
The Latest on: Machine learning clinical trials
- Hanmi to Streamline Clinical Trials and Bolster Quality of Results with Medidata Cloud on August 23, 2018 at 10:53 am
Hanmi will utilize Medidata Edge Central Monitoring to: Analyze clinical trial data through machine learning, and identify errors and/or outliers Monitor and analyze risk during clinical procedures Me... […]
- Cytobank Awarded NIH Grant to Scale Its Cloud-Based Machine Learning Platform for Accelerating Immunotherapy Translational Research on August 1, 2018 at 7:26 am
“In our research we have found that high-dimensional machine learning-based analyses of clinical samples, like those enabled by Cytobank, can often reveal important cell populations that are missed wi... […]
- GV invests in medical machine learning startup Owkin on May 23, 2018 at 5:56 am
Owkin, a medical research machine learning startup ... “Owkin has assembled a talented team of experts in applied machine learning with clinical data experience,” noted GV general partner Adam Ghobara... […]
- Beta Bionics Receives IDE Approval from the FDA to Begin a Home-Use Clinical Trial Testing the New iLet™ Bionic Pancreas System on May 21, 2018 at 5:00 am
which incorporate machine-learning artificial intelligence to autonomously control glycemia. These mathematical dosing algorithms were developed in the Damiano Lab at Boston University and refined bas... […]
- Reverie Labs uses new machine learning algorithms to fix drug development bottlenecks on March 16, 2018 at 6:16 am
... can take years of research and cost millions of dollars before they are even ready for clinical trials. Several biotech startups are using machine learning to revolutionize the process and get dru... […]
- American Heart Association and Duke partner to accelerate machine learning and AI on March 14, 2018 at 3:22 am
The American Heart Association and the Duke Clinical Research Institute on Monday unveiled a partnership to try out machine-learning techniques to find new ways to analyze data and drive scientific di... […]
- Improving clinical trials with machine learning on November 14, 2017 at 4:00 pm
Machine learning could improve our ability to determine whether a new drug works in the brain, potentially enabling researchers to detect drug effects that would be missed entirely by conventional sta... […]
- Karyopharm and Medidata Expand Clinical Trial Partnership on April 4, 2017 at 5:39 am
"As we advance our most promising cancer therapies, it is vital that Karyopharm embraces the latest technologies and evolving trends in the clinical trials space. Adopting Medidata's machine-learning ... […]
- Discoveries by GNS Healthcare Causal Machine Learning and Simulation Platform, REFS, Reveal Mechanisms Driving Key Clinical Outcomes in Multiple Myeloma on December 5, 2016 at 4:00 pm
--(BUSINESS WIRE)--GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to massive ... Several drivers of clinical outcomes in multiple myeloma di... […]
- Breakthrough Clinical Trial to be featured on CNN: Reductions in Suicidality, Depression, and Post-Traumatic Stress on November 10, 2016 at 4:07 pm
In this study service members whose doctors followed a machine learning treatment recommendation in their ... doctors did not follow the PEER Interactive recommendations. Clinical Trial Demonstrates I... […]
via Google News and Bing News